Series D Funding Strengthens Early Cancer Detection Push
ClearNote Health has secured $52 million in Series D funding. The company focuses on early detection of deadly cancers. It develops noninvasive blood based diagnostic tools. The funding round brings total capital raised above $185 million. The company aims to scale access to early screening technologies globally.
The round was led by founding investor Mattias Westman. A global long only active manager also co led the investment. Additional participants included Sandy Weill. He is former CEO and chairman of Citigroup. Dr Stephen Quake also participated. He is ClearNote Health co founder from Stanford University.
The company also attracted a Seattle based family office. Several other institutional investors joined the round. These include US and international backers. Investors highlighted strong scientific progress. They also cited growing demand for early cancer detection tools.
ClearNote Health said proceeds will support expansion plans. It will invest in commercial growth. It will also fund clinical study execution. Product development will also receive increased investment. The company aims to scale its Avantect portfolio and Virtuoso platform.
AI and Epigenomics Drive Noninvasive Cancer Innovation
ClearNote Health builds its platform on epigenomic science. It uses blood based signals to detect cancer. These signals reflect biological changes in cells. The system analyses differences between healthy and cancerous samples. It applies machine learning to improve accuracy.
The company’s core technology is the Virtuoso platform. It combines epigenomics with artificial intelligence. It also integrates bioinformatics systems. This allows high sensitivity detection of cancer markers. The platform is designed for early stage identification.
ClearNote Health also develops Avantect tests. These are noninvasive blood tests. They target pancreatic and ovarian cancers. These cancers are often detected late. Early detection can improve treatment outcomes. The company aims to change that timeline.
The Avantect pancreatic test has shown strong performance. It uses a multiomic approach. It combines multiple biological signals. It also uses machine learning optimisation. This improves detection sensitivity and specificity. Clinicians can make faster decisions using these results.
The company said its technology supports clinical precision. It reduces reliance on invasive procedures. It also improves accessibility of screening. ClearNote Health believes early detection is the most important factor. It aims to shift diagnosis earlier in the disease cycle.
Leadership Expansion Signals Commercial Acceleration
Experienced leadership drives scaling of AI-powered cancer diagnostics, accelerating global access to early detection technologies. Source: Created by Ventureburn
ClearNote Health also announced a leadership expansion. Kevin Keegan has been appointed president and chief operating officer. He brings nearly 30 years of diagnostics experience. His background includes roles in oncology and molecular diagnostics.
Keegan previously worked at BD. He also held senior positions at Illumina and Hologic. At Illumina, he led oncology operations. He oversaw launch of a major tumour profiling test. His experience spans global diagnostics commercialisation.
He said ClearNote Health has strong potential. He highlighted its purpose built platform. He believes early diagnosis can transform outcomes. He said he is focused on expanding access to genomic tools. He aims to support patients at elevated risk.
CEO Dave Mullarkey said the appointment strengthens execution. He said the company is entering a scaling phase. He highlighted commercial momentum across products. He also noted increasing market demand. He said leadership depth is essential for expansion.
Investors also welcomed the leadership move. They said experienced operational leadership is critical. They believe ClearNote Health is entering a growth stage. They highlighted strong alignment between science and execution.
More News: Pace Raises $46 Million to Scale AI Insurance Operations
Clinical Expansion and Global Access Strategy
ClearNote Health will expand clinical research programmes. It will scale ongoing studies across cancer types. It will also expand product validation efforts. These studies support regulatory and commercial adoption. The company aims to strengthen clinical confidence.
The firm plans broader global access to its tests. It targets high risk patient populations. It aims to support earlier intervention strategies. It believes noninvasive testing can improve screening rates. It also expects increased adoption in healthcare systems.
The company operates a CLIA certified laboratory. It is also CAP accredited. It holds approval from the New York State Department of Health. Its headquarters are in San Diego. These certifications support clinical reliability.
ClearNote Health has developed its platform at Stanford University origins. It was built in the Stephen Quake laboratory. The system integrates advanced computational biology. It also uses artificial intelligence models. These tools support scalable cancer detection.
The company said demand for early detection is rising. Healthcare systems are under pressure. Costs and late diagnosis remain key challenges. ClearNote Health believes its platform addresses both issues. It aims to provide scalable and affordable diagnostics.
ClearNote Health’s funding reflects rising investment in advanced diagnostic platforms. Early detection technologies continue to attract strong institutional backing.
ClearNote Health’s $52 million Series D strengthens its position in early cancer detection. The company combines epigenomics, machine learning, and clinical diagnostics into a single platform. It now moves into a global scaling phase supported by strong investor and leadership expansion.
To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.
